Using vorolanib for treating advanced kidney cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study focuses on patients with unresectable or metastatic renal cell carcinoma who are receiving vorolanib as a second-line treatment. Eligible participants will be monitored for survival outcomes, with data collected for both retrospective and prospective analyses. The study aims to compare real-world survival data with previous findings from the CONCEPT study and conduct a multi-factor stratified analysis of vorolanib's efficacy. Vorolanib is a novel multi-target kinase inhibitor designed to inhibit tumor growth and angiogenesis in various cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects have fully understood and voluntarily signed the informed consent form (ICF);
* 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1;
* Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components;
* According to RECIST (version 1.1), there are targets that are considered to be observable;
* The main organs function well.

Exclusion Criteria:

* A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);
* Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy within 4 weeks prior to the initial study;
* Had major surgery within 4 weeks prior to initial study dosing (as judged by the investigator) or was in recovery;
* A history of severe drug allergy, including but not limited to antibody drugs;
* Patients with contraindications for immunotherapy restart;
* A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy. Patients with thyroid, suprarenal, or hypopituitarism that can be controlled by hormone replacement therapy alone, type 1 diabetes mellitus, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study;
* Toxicity did not resolve after previous antitumor therapy, i.e., regression to baseline, NCI-CTCAE 5.0 level 0-1 (except for alopecia), or levels specified in inclusion/exclusion criteria. Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the drug under study may be included in the study;
* Have central nervous system metastases and/or cancerous meningitis;
* Known history of clinically significant liver disease, including those infected with viral hepatitis activity;
* Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients with no need to drain effusion or no significant increase in effusion after 3 days of stopping drainage could be included);
* Patients with any severe and/or uncontrolled disease;
* Renal failure requires hemodialysis or peritoneal dialysis;
* Have or have a suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;
* History of live attenuated vaccine vaccination within 4 weeks prior to the initial study or expected live attenuated vaccine vaccination during the study period;
* Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders;
* Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.

Where it's running

• Jinling Hospital
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Le Qu, M. D.
• Email: septsoul@hotmail.com
• Phone: +86 15720625951

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CD70-targeted immunoPET Imaging of Kidney Cancer

  This study is testing a new imaging technique that uses a special marker to help doctors see kidney cancer more clearly.

  Recruiting Phase 2 RenJi Hospital · Shanghai, Shanghai Municipality · NCT06680089

• Using 18F-Fluciclovine PET/CT to Predict Outcomes of Prostate Cancer Therapy

  This study is testing if special imaging can help predict how well a new prostate cancer treatment works for patients with advanced disease.

  Recruiting Phase 4 VA Greater Los Angeles Healthcare System · Los Angeles, California · NCT06706921

• Combination of chemotherapy and immunotherapy for advanced penile cancer

  This study is testing a new treatment combining chemotherapy and immunotherapy for adults with advanced penile cancer to see if it helps them respond better to therapy and manage their disease.

  Recruiting at 2 sites Phase 2 The Netherlands Cancer Institute · Leuven and 1 other locations · NCT06353906

• Treatment with STAR0602 for advanced solid tumors

  This study is testing a new treatment called STAR0602 to see if it can help people with advanced solid tumors by looking at how safe it is and how well it works.

  Recruiting at 16 sites Phase 1/2 Marengo Therapeutics, Inc. · Sacramento, California and 18 other locations · NCT05592626

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Benchmarking AI language models against tumor boards for oncology treatment decisions

  This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt and 4 other locations · NCT07739121

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.